|
Improvement of Quality of Life (QoL) Using Preference-Oriented QoLMonitoring in Patients with Lung Cancer
RECRUITINGN/ASponsored by University of Bayreuth
Actively Recruiting
PhaseN/A
SponsorUniversity of Bayreuth
Started2024-02-15
Est. completion2025-02-15
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06252233
Summary
The purpose of the study is to determine whether a preference-oriented quality of life monitoring with defined diagnostic and therapeutic options improves quality of life in patients with lung cancer during routine follow-up care.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: 1. primary diagnosis of lung cancer (ICD C33/C34, all stages) 2. treatment in one of six recruiting hospitals treating patients with lung cancer (University Hospital Regensburg, Hospital Barmherzige Brüder Regensburg, Hospital Bayreuth, Hospital Coburg, Hospital Kulmbach, Hospital Bamberg); 3. difference between date of histology and date of study entry not exceeding 2 months; 4. informed consent; Exclusion Criteria: 1. unavailability of a study clinician for patient recruitment; 2. patient misclassified in the candidate list (no primary diagnosis, no lung tumour); 3. coordinating practitioner refuses trial participation; 4. patient outside the defined study region (Germany, Bavaria: Upper Palatinate, Lower Bavaria, Upper Franconia); 5. age under 18 years; 6. pregnancy/ breastfeeding; 7. patient unable to fill out the QoL questionnaire (physical, psychological, cognitive, language reasons); 8. patient refuses trial participation
Conditions3
CancerLung CancerQuality of Life
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorUniversity of Bayreuth
Started2024-02-15
Est. completion2025-02-15
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06252233